Berberine Shields the Liver While Boosting Evodiamine's Colitis-Fighting Power
Combining two traditional herbal compounds fixes a dangerous liver toxicity problem while making colitis treatment significantly more effective.
Summary
Evodiamine (EVO), a bioactive compound from the herb Euodiae Fructus, shows promise against colitis but causes liver toxicity. Researchers found that co-administering berberine (BBR) — from Rhizoma Coptidis — not only neutralizes EVO's hepatotoxic effects but also enhances its anti-colitis efficacy. In mouse models, BBR corrected EVO-induced disruptions in fatty acid metabolism and cholesterol synthesis by modulating key targets including ACSL1, CPT1B, SQLE, and DHCR7. The combination also suppressed IL-17/NF-κB inflammatory signaling, restored gut barrier integrity, and rebalanced the gut microbiome. The enzyme ACSL3 was pinpointed as the central therapeutic target linking lipid metabolism to inflammation control, offering a molecular explanation for why this classic herb pairing works.
Detailed Summary
Traditional herbal medicine has long paired Euodiae Fructus with Rhizoma Coptidis for treating gastrointestinal inflammation, but the precise molecular mechanisms behind this pairing — and its safety profile — remained poorly understood. This study provides a detailed mechanistic investigation into how combining evodiamine (EVO) and berberine (BBR), the primary bioactive compounds from each herb respectively, resolves a critical safety issue while synergizing therapeutically against colitis.
EVO alone caused significant liver damage in C57 mice, marked by elevated AST/ALT enzymes, hepatic steatosis, and disrupted fatty acid β-oxidation and cholesterol synthesis pathways. This hepatotoxicity was linked to dysregulation of metabolic genes including ACSL1, CPT1B, SQLE, and DHCR7. When BBR was co-administered, these metabolic disturbances were corrected, liver pathology improved, and hepatic enzyme levels normalized — demonstrating a clear hepatoprotective effect of BBR against EVO-induced injury.
In colitis mouse models, the combination outperformed either compound alone. The dual therapy reduced mucosal damage, restored goblet cell populations critical for gut barrier function, suppressed pro-inflammatory cytokines, and rebalanced gut microbiota composition. Mechanistically, the combination inhibited IL-17/NF-κB inflammatory signaling and upregulated tight junction proteins that maintain intestinal wall integrity.
Using integrated RNA-seq transcriptomics and metagenomic sequencing, the team identified ACSL3 — a fatty acid metabolism enzyme — as the pivotal molecular hub connecting lipid peroxidation to inflammatory pathway activation. In LPS-stimulated colon cells, the EVO+BBR combination suppressed ACSL3-mediated lipid peroxidation, thereby dampening IL-17/NF-κB-driven inflammation.
Caveats include the preclinical nature of this work; all findings are from mouse models and cell lines. The clinical translatability of these specific molecular targets and the optimal dosing ratio for human use remain to be established.
Key Findings
- Berberine co-administration eliminated evodiamine-induced liver toxicity by restoring fatty acid β-oxidation and cholesterol homeostasis.
- The EVO+BBR combination outperformed monotherapy in reducing colitis mucosal damage and restoring gut barrier proteins.
- ACSL3 was identified as the central target linking lipid peroxidation to IL-17/NF-κB inflammatory activation in colon cells.
- Combination therapy corrected gut microbiota dysbiosis and suppressed pro-inflammatory cytokines more effectively than either compound alone.
- Key metabolic regulators ACSL1, CPT1B, SQLE, and DHCR7 were modulated by BBR to counteract EVO hepatotoxicity.
Methodology
Researchers used C57 mouse models for both normal and colitis conditions, comparing EVO alone versus EVO+BBR combination. RNA-seq transcriptomics on liver and colon tissues was integrated with metagenomic sequencing of fecal samples for mechanistic analysis. Findings were validated with molecular biology experiments and LPS-stimulated NCM460 human colon cell assays.
Study Limitations
All experiments were conducted in mouse models and cell lines, limiting direct clinical applicability. Optimal human dosing ratios and long-term safety profiles of the EVO+BBR combination have not been established. The abstract does not specify whether gut microbiota restoration was causally linked to therapeutic outcomes or was correlative.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.